secwatch.observer — SEC 8-K summary
======================================

Issuer:     COMPASS Pathways plc (CMPS)
CIK:        0001816590
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001628280-24-021352
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Pathways Q1 net loss $35.2M ($0.55/share); phase 3 TRD on track; PTSD phase 2 positive
--------------------------------------------------------------------------------

- Net loss $35.2M vs $24.2M in Q1 2023; EPS loss $0.55 vs $0.57.
- Cash $262.9M at March 31, 2024, up from $220.2M; net $63.5M raised via ATM and warrants.
- COMP360 phase 3 for TRD on track: COMP005 top-line Q4 2024, COMP006 mid-2025.
- Phase 2 PTSD open-label: 25mg single dose well tolerated; CAPS-5 reduction 29.9 pts at week 4.
- Michael Gold joins as Chief R&D Officer May 20; Trevor Mill departs as Chief Development Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816590/000162828024021352/0001628280-24-021352-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816590/000162828024021352/cmps-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-021352

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer